Coverage and Payment for Prescription
Drugs Under Medicare Part B:
A Complex Patchwork
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OVERVIEW — As part of the diverse discussions around health care

reform, many have looked to refining Medicare payment systems
as a way to give health care practitioners and providers greater
incentives to deliver care more efficiently, and thus slow health care
spending growth. Understanding how Medicare currently pays for
Part B services, including drugs covered under Part B, is essential to
understanding the potential impact of these types of reforms. Most
items and services covered under Part B, including most Part B
drugs, are paid individually, which means practitioners and providers generally receive more payments for providing more services.
Some reform proposals would expand the use of bundled payments
under Medicare to pay for items and services as a group, rather
than separately, to curb incentives to provide unnecessary care. If
such reforms were to include Part B drugs, it would be a significant
change from current payment policies. A close look at coverage and
payment for Part B drugs reveals complex policies and interactions
with Part D drug coverage.
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Medicare Part B covers certain outpatient drugs used in specific settings or to treat specific conditions, and its coverage has expanded
incrementally since Medicare was created in 1965. Multiple payment systems and fee schedules are used to establish the payments
for Part B drugs. Those payment systems and fee schedules may
produce different payment amounts for practitioners and providers and different cost-sharing for beneficiaries for the same drug,
depending on the setting in which it is administered. As a result of
various coverage requirements and payment methodologies, practitioners, providers, beneficiaries, Medicare claims processing contractors, and prescription drug plans must determine which part
of Medicare should be paying for a drug under particular circumstances, which, in turn, will determine how much Medicare and the
beneficiary will pay.
This paper explores (i) coverage: the types of drugs and circumstances under which they may be covered by Part B and (ii) payment:
how Part B payment and beneficiary cost-sharing is determined in
different treatment settings.

M EDICARE DRUG COV ERAGE
All of the different parts of Medicare—Parts A, B, C and D—pay for
prescription drugs. Parts A and B of Medicare pay for inpatient and
outpatient medical services, respectively. Together they are referred
to as traditional, or fee-for-service (FFS), Medicare. Part C, the Medicare managed care program, pays private plans a monthly rate to
cover the same services covered under traditional Medicare.1 Part
D, the Medicare prescription drug benefit, pays private plans to administer most outpatient drug coverage, but under certain circumstances some outpatient drugs may be covered under Part B.2 The
Centers for Medicare & Medicaid Services (CMS) has responsibility
for the four parts of Medicare and contracts with claims processing
contractors and private plans to administer the program.
Ba s i c s of Pa r t B D r u g C ove ra g e

Part B drugs are primarily administered in physician offices, hospital
outpatient departments, or end stage renal disease (ESRD) facilities
or with the use of durable medical equipment (DME), such as an infusion pump. In 2007, the Medicare Payment Advisory Commission
3
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Part B Drug Spending in 2007 		
by Setting

Total spending — $16.8 billion
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(MedPAC) estimated that payment for Part B drugs
in these settings totaled $16.8 billion.3 To put this
number in perspective, Part B drugs accounted for
roughly 10 percent of all spending on Part B services
in 2007 and one-third of the amount spent on Part D
drugs in that year.4 Figure 1 shows a breakdown of
spending on Part B drugs in 2007 by setting.
While Part B covers more than 675 individual
drugs, spending is concentrated on a small number of drugs: 10 account for almost half of Part B
drug spending.5 Most of those high-cost drugs are
for treatment of cancer or the side effects of chemotherapy such as anemia.

Source: Medicare Payment Advisory Commission (MedPAC), A
Data Book: Healthcare Spending and the Medicare Program, June
2009; available at www.medpac.gov /documents /Jun09DataBook
EntireReport.pdf.

Part B drug coverage grew in a piecemeal fashion over
many years through many different pieces of legislation. Table 1 (next page) shows examples of specific
coverage added by some of the major Medicare bills
passed over the last two decades. The cost of expanded coverage was
often an important consideration, so the statutory language can be
extremely specific about when and for whom a drug is covered.
To be covered under Part B, a drug must fulfill two requirements.
First, it must be included in one of the groups of items and services
listed in the statute that are covered by Medicare.6 Second, individual items that fall within a covered group must also be considered
“reasonable and necessary” under the Medicare law.
Most Part B–covered drugs are considered part of a larger group of
services such as physician services, hospital outpatient services, or
ESRD services.7 Generally, Part B covers five types of drugs:
• Physician-administered drugs
• DME-administered drugs
• Certain oral drugs
• Vaccines
• Other drugs in certain circumstances
Physician-administered drugs — Drugs that are administered by a physi-

cian or professional staff in a clinical setting, such as a hospital outpatient department or physician’s office, typically through infusion
4
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Table 1
Examples of Bills Expanding Coverage of Part B Drugs
Bill
Omnibus Budget
and Reconciliation
Act (OBRA) of 1993

Coverage Provision
Covered off-label uses of anti-cancer
drugs that are cited in certain compendia
or supported by clinical evidence in peerreviewed medical literature

Balanced Budget
Act (BBA) of 1997

Covered oral anti-nausea drugs for use
within 48 hours after chemotherapy

Balanced Budget
Refinement Act
(BBRA) of 1999

Extended time period of coverage of
immunosuppressive drugs

Benefits Improvement
and Protection
Act (BIPA) of 2000

Eliminated time limitation on coverage
of immunosuppressive drugs

Medicare
Modernization Act
(MMA) of 2003

Covered intravenous immunoglobulin
(IVIG) for treatment of primary immune
deficiency in the home

or injection, are covered under Part B. Because the act of administering the drug is covered as a physician or hospital outpatient service,
the drug being administered is also covered. Such drugs are often
referred to as “incident to” drugs because they fall into the group of
covered services that are “incident to a physician service.”
The law requires that “incident to” drugs be classified as “not usually self-administered,” which means that the drug cannot be administered by the patient or caregiver more than 50 percent of the time.
Drugs that are administered intravenously or intramuscularly are
presumed to be not self-administered, whereas oral drugs are presumed to be self-administered. Drugs that are administered through
injection into the layer of fatty tissue just below the skin (called a
subcutaneous injection) may or may not be self-administered. Subcutaneous drugs used to treat chronic conditions are more likely to
be considered self-administered than those to treat acute conditions.8
5
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CMS has instructed its claims processing contractors to determine
whether or not a drug is usually self-administered for their jurisdictions.9 Each contractor publishes its list of usually self-administered
drugs, and those drugs are not covered under Part B in the contractor’s jurisdiction, even if the drug is administered by a physician.
In 2008, the number of drugs on the usually self-administered lists
ranged from 14 for one contractor to 41 for others.10
DME-administered drugs — CMS interprets the Medicare DME benefit

to include certain drugs because they are essential to the functioning of items that are covered under Part B as DME. For example, a
nebulizer is a device that administers aerosolized medicine to treat
respiratory disease; it stands repeated use and is covered under the
DME benefit. Inhalation drugs are covered under Part B when used
with a nebulizer, because the nebulizer could not fulfill its medical
purpose without the drug. Inhalation drugs provided through other
mechanisms that are not considered DME, such as multi-dose inhalers, are not covered under Part B. In addition to inhalation drugs, infusion drugs may be covered under the DME benefit if administered
through an infusion pump that is covered under the benefit.
Limitations that apply to other DME items also apply to drugs covered under the DME benefit. For example, as defined by statute, the
DME benefit does not apply to beneficiaries in an inpatient setting
such as a skilled nursing facility (SNF) or hospital. If administered
in an inpatient facility, a drug covered under the DME benefit in a
patient’s home would not be covered under Part B, even if Medicare
is not paying for the inpatient stay.11
Oral drugs — Most oral drugs are not administered by a physician

and generally are considered self-administered. However, the law
does allow for Part B coverage of certain oral drugs under specific
circumstances:
• Immunosuppressive drugs for beneficiaries who have received a
Medicare-covered organ transplant
• Oral anti-cancer drugs that have the same active ingredients and
are used for the same indications as forms of the drug that are covered incident to a physician service
• Oral anti-nausea drugs if used as part of an anti-cancer regimen
as a replacement for intravenous drugs within 48 hours of chemotherapy administration

6
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Oral drugs are typically obtained from community or mail order
pharmacies, whose interaction with Part B is limited. This may introduce additional administrative complexities for these pharmacies.
Prescription drug plans must sort out whether these drugs are covered under Part B or Part D. (See text box below.)
Vaccines — The law requires Part B coverage of preventive vaccines

for influenza, pneumococcus, and hepatitis B. Part B does not cover
most other preventive vaccines, but they may be covered under Part
D. However, Part B will cover vaccines when they are used for the
treatment of illness or injury (for example, a tetanus shot after stepping on a nail).
Other drugs — The Medicare statute requires coverage of a few other

drugs under very specific circumstances. For example, Part B covers parenteral nutrition (feeding a person intravenously), but only for
patients who are receiving such therapy because of a non-functioning digestive tract. Intravenous immunoglobulin (IVIG) provided in
the home is covered under Part B for patients with primary immune

Part B vs. Part D
The same drug may be covered under different parts of the Medicare program, depending on the circumstances under which it is administered. By law, drugs covered by Part A or B of Medicare are not Part D
drugs. The complexity and variation in Part B coverage can make it challenging to determine whether a drug
is covered under Part B or Part D. Medicare fee-for-service claims processing contractors and Part D plans
must sort through these intricacies to determine which part of Medicare should be paying for a particular
drug. Prescription drug plans must be familiar with both general Part B coverage and with the specific
drugs that are covered under Part B by contractors in their plan coverage area. Drugs that are considered
usually self-administered by one contractor in one area—and therefore could be Part D drugs—may be
covered under Part B by other contractors in other areas. Mode of administration suggests whether Part B
or Part D is probably responsible for coverage, but is not a definitive guideline. The key factor is how the
drug is prescribed and dispensed in the specific circumstance for a particular patient. A drug typically
covered by Part B may be a Part D drug if it is filled at a community or mail order pharmacy.
This complexity precludes prescription drug plans from basing coverage determinations solely on the item
being prescribed, although this may be the only information initially provided to them. The structure of
Part D, which puts plans at risk to manage beneficiary drug costs, creates incentives for plans to ensure
that they do not pay for drugs that should be paid for under Part B.
The Part B versus Part D determination can affect how much is paid for the drug in question and how
much cost sharing the beneficiary must pay. See the "Beneficiary Out-of-Pocket Costs" (p. 15) and Appendix
B (p. 22) for more information.
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deficiency disease. Blood clotting factor for hemophilia patients is
covered even if it is self-administered. Also covered under Part B are
blood products, antigens, therapeutic radiopharmaceuticals, and diagnostic radiopharmaceuticals and contrast media for imaging.

M EDICARE PAY M EN T P O L ICY
Setting an appropriate payment rate for Part B drugs has been challenging for policymakers. Paying too much or too little can distort
clinical decision making about the use of certain drugs, which can
have repercussions on the health of Medicare beneficiaries and the
financial well-being of the program.
Paying for drugs at rates that are significantly greater than the cost
of acquiring the drugs creates incentives for physicians to provide
more drugs.12 Paying too little for drugs also has adverse consequences. Continued underpayment for a drug could affect beneficiary access if providers are unable or unwilling to offer that drug
because the payment does not cover their costs. The effect of underpayment may not be that a drug becomes unavailable but rather
that it is administered in a different setting. For example, rather than
administering the drug in the office where the physician practice is
responsible for purchasing the drug, the physician could refer the
beneficiary to the hospital to receive the drug. Under this scenario,
the hospital would be responsible for purchasing the drug. Changing where the drug is obtained could inconvenience the beneficiary,
and it could change the Medicare payment for the drug and its administration. Alternatively, the physician may be willing to administer the drug in the office but not provide it, recommending that
the patient obtain the drug from a community pharmacy and bring
it to the office to be administered. This practice, called “brown bagging,” raises concerns for some about the appropriate handling of
the drug between the time it is dispensed by the pharmacy and
administered by the doctor.13
Pay m e n t Ba s i c s fo r Pa r t B D r u g s

In understanding Medicare payment policy, it is important to remember that Medicare pays physicians, hospitals, and suppliers who
have purchased drugs from manufacturers, wholesalers, or group
purchasers. The Medicare program does not pay drug manufacturers
8
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directly for their products. The rates paid to practitioners and providers are set prospectively, based on market prices for the drugs.
Because of the size of the Medicare program, the appropriate price
in a market without Medicare as a purchaser may be very different
from the price determined by a market that includes Medicare. With
45 million, primarily aged, beneficiaries, the Medicare program has
a substantial effect on drug sales volume and market price. Medicare
approximates what an appropriate price should be through different
approaches in different settings. These approaches include the average sales price (ASP), the average wholesale price (AWP), and the
acquisition cost of the drug.
Medicare law specifies the basis of payment in different clinical settings and, in most cases, also specifies the percentage of the amount
that Medicare will pay. Payment for drugs administered in physician offices and ESRD facilities and inhalation drugs administered
through DME is based on the ASP. Since the ASP reflects the average
sales price, some sales occurred at or below that price and others occurred above that price. In most instances, the payment rate required
by law is greater than the ASP, allowing most providers to be able
to obtain the drug without losing money on the transaction.14 Payment for infusion drugs administered through DME and the three
preventive vaccines covered by Part B when provided in a physician
office is based on the AWP. Payment for drugs
administered in a hospital outpatient departTable 2
ment or an ambulatory surgical center is based
Basis for Part B Drug Payments by Setting
on the average hospital acquisition cost, plus an
amount for pharmacy overhead and handling
Setting Payment Basis
costs. Table 2 shows the payment percentages
Physician Office 106% of ASP
for each setting. The different approaches to
ESRD Facility 106% of ASP
calculating prices under Part B are described
Inhalation Drugs 106% of ASP
below, and Appendix A provides a table sumDME
Infusion Drugs 95% of AWP*
marizing the terms.
Average wholesale price — Prior to 2005, payment

for most Part B drugs was based on the AWP as
listed in certain data sources such as Red Book.
Often referred to as a “sticker price” that does
not incorporate common discounts and rebates,
AWP is a misnomer because it is neither an average price nor the price paid by wholesalers. Several organizations, including the Government

Hospital Outpatient
Department / Ambulatory
Surgical Center

Average hospital acquisition
cost for the drug**

Preventive vaccines

95% of AWP

Oral drugs provided by
a pharmacy supplier

106% of ASP

* As calculated October 1, 2003.
** In 2009, hospital outpatient department and ambulatory surgical center
payment rates based on hospital acquisition costs are 104% of ASP.
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Accountability Office and the Office of the Inspector General (OIG)
at the U.S. Department of Health and Human Services, studied the
relationship between AWP and practitioner and supplier acquisition costs and found that practitioners and suppliers could obtain
the drugs for considerably less than Medicare’s AWP-based payment
rate.15 The Medicare Modernization Act of 2003 (MMA) subsequently
shifted the basis for Medicare payment for most Part B drugs provided in the physician’s office from AWP to the average of the actual
prices paid by all purchasers in the United States (the average sales
price) for the drug beginning January 1, 2005.
Following enactment of the MMA, the only payment for Part B drugs
still based on AWP are drugs provided through infusion pumps under the DME benefit, certain blood products, and the three Part B preventive vaccines when provided in settings other than a hospital outpatient department.16 The payment rates for the vaccines and blood
products are updated to reflect current AWPs. For DME infusion
drugs, payment is based on the AWP in effect on October 1, 2003.
Average sales price — CMS calculates the ASP using data submitted

by manufacturers on the sales prices of their drugs. Excluded from
the ASP calculation are sales to certain government programs and
safety net hospitals, as well as sales under state pharmaceutical assistance programs and Part D.17 ASP is not to be confused with the
average manufacturer’s price (AMP) used in the Medicaid drug rebate program.18 AMP is a similar calculation (see text box).

ASP vs. AMP
Medicare’s ASP and Medicaid’s AMP are both measures of average sales but they differ in several
important ways. The universe of drug sales included in the AMP calculation is more limited,
including only sales to the “retail class of trade”; in other words, pharmacies available to the
general public. ASP includes sales for all classes of trade except those under certain government
programs. Specific exclusions for government programs do not apply under AMP, so a sale to
the retail class of trade may be excluded from ASP and included in the AMP calculation.
Most discounts and rebates are included in the calculations of both ASP and AMP. The exception is customary "prompt pay" discounts, which are included in ASP but excluded from AMP.
In general, AMP is greater than ASP.
Source: CMS, Medicaid: Prescription Drug Final Rule, July 17, 2007, available at http://edocket.access.gpo.gov/
2007/07-3356.htm.
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Unlike AWP, ASP includes the various discounts and rebates offered
by manufacturers that reduce the price paid for their drugs. The arrangements between manufacturers and purchasers are varied and
complex and can include discounts for prompt payment as well as
those tied to the quantity or combination of drugs purchased. CMS
has revised its regulations multiple times to attempt to fully account
for the diverse arrangements used in the marketplace. However,
questions remain about how well ASP captures the discounts and
rebates that apply to the price paid by providers. Some discounts are
difficult to assign to specific drugs for particular periods because
they are based on total purchases for the year or tied to the combination of drugs purchased. ASP might overstate the actual price
for the drugs subject to these price concessions if they are not appropriately attributed to the drugs involved. ASP might understate
the price paid by providers if it reflects discounts to wholesalers that
are not passed on to providers or if it does not fully reflect additional
fees charged by wholesalers.19
Manufacturers provide product-specific sales data and CMS calculates the ASP, taking into consideration other products assigned to the
same payment code. In some cases, only one drug is assigned to a payment code. In other instances, multiple drugs may be assigned to the
same code, such as a brand name drug and its generic alternative.20
Manufacturers must submit the ASP data for their products within
30 days of the end of each calendar quarter. CMS reviews the data
and then calculates and releases the payment-level ASP data to its
contractors and the public. Because of the time necessary to gather, submit, and process ASP data, there is a six-month lag between
when the sales occur and when the price of those sales will affect the
Medicare payment rates.
The MMA required the OIG to compare the ASP with two other
methods for calculating price: AMP under Medicaid, and the price
a prudent purchaser would pay for the drug (the widely available
market price, or WAMP). The statute requires that CMS adjust payments for drugs that exceed AMP or WAMP by a certain threshold
(to date the threshold has been 5 percent). Most recently, the OIG
found that 5 percent of the drugs studied exceeded the threshold for
the third quarter of 2008, and 80 percent of those drugs had exceeded the threshold in previous quarters.21 Because of concerns about
the lag between the time period involved in the study and when the

11
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ASP study findings become available, CMS has not made any adjustments to the payment rates based on the OIG findings.
Acquisition cost — In addition to AWP and ASP, Medicare may deter-

mine payment for a drug based on its acquisition cost, or the amount
a Medicare provider actually pays for the drug in combination with
the overhead costs to prepare the drug for administration. Because
providers do not report their actual costs to Medicare, CMS must
estimate those costs.

For drugs provided in hospital outpatient departments, CMS uses
the information providers submit on claims to estimate the combined acquisition cost of drugs plus allocated pharmacy overhead.
When a provider bills Medicare for treating a patient, it submits a
claim that includes dollar values called charges for the services provided. The charge data are used to estimate the cost of providing the
service. Because of the time necessary to receive and process claims
and then for CMS to analyze information on those claims, the claims
data used to set payment rates for a given year are typically two
years old (that is, the data used to update the 2009 prospective payment systems are from 2007). The data are adjusted to approximate
the later year costs.
The payment for certain drugs is packaged into payment for associated procedures. For others, the payment is made separately. For
those drugs that are separately paid, the payment is based on the
overall relationship between the costs of average acquisition and
pharmacy overhead for hospital outpatient drugs (derived from the
claims data) and the ASPs for those drugs. Separately payable drugs
under the Outpatient Prospective Payment System (OPPS) were paid
at ASP + 5 percent in 2008 and ASP + 4 percent in 2009.22
There have been attempts to obtain acquisition data through provider surveys. Most recently, GAO conducted a survey of drug acquisition costs for hospital outpatient departments in 2004 that was
considered in setting OPPS payment rates.23 Providers maintain
their acquisition data in a myriad of ways, making it difficult for the
providers to gather the data and present it in a standardized form.
Furthermore, a sufficient number of providers must participate in
the survey in order to make its findings representative of providers
who are not included. These complications make provider surveys
costly and time-consuming, both to participate in and to administer.
Once completed, the survey results present a snapshot of acquisition
12
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costs at a particular point in time that can be difficult to accurately
update for later periods.24
Bu n dl e d Ve r s u s S e p a ra te Pay m e n t

In some instances, Medicare pays for an item or service in combination or bundled with payment for other associated services. For
example, Medicare pays for most inpatient hospital care by providing a prospectively determined lump sum payment for all items and
services furnished during a hospital stay. Providing more services
during a hospital stay generally will not increase Medicare payment.
In contrast, most items and services under Part B are paid separately.
Furnishing more items and services will increase Medicare payment.
Most, but not all, Part B drugs currently receive separate payment.
The setting in which a drug is administered affects whether it is paid
separately. Drugs provided in a physician office are paid separately.
In other settings such as hospital outpatient departments and ESRD
facilities, payment for some items and services is provided together,
including some drugs. In those settings, newer or more expensive
drugs often receive separate, individual payment. In ESRD facilities,
drugs that were not included in the base payment unit (called the
composite rate) when it was developed in the early 1980s, are paid
separately. The ESRD payment system is being revised to expand
the base bundle of services. By law, the expanded bundle, which is
expected to be implemented January 1, 2011, will include drugs that
are now separately payable.
The OPPS uses a dollar threshold cost per day to determine whether
a drug is paid separately. If the per-day costs for a drug are less than
or equal to the annual drug packaging threshold, payment for the
drug is included in payment for the services with which it is used.
If the drug’s costs are greater than the threshold, then hospitals may
receive separate payment for the drug. The threshold is updated annually and is set at $60 for 2009.
Some have suggested that expanding the use of bundling could
help address increasing spending on Part B drugs.25 Under current
law, CMS could potentially expand bundling under certain payment systems such as the OPPS, or could experiment under a demonstration project with bundling payments for all services related
to a certain disease such as cancer.26 However, Congress would

13
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need to change the Medicare statute to incorporate bundled payments for drugs on a broader scale.
Pay m e n t s in D if f e re n t S e t tin g s

Because payment rates and bundling policies differ, payment for the
same drug can vary considerably from setting to setting. The most significant contrast is between the physician office and the hospital outpatient department, since most Part B–covered drugs can be provided
in either setting. Drugs provided in physician offices are, by law, paid
at ASP + 6 percent. Separately payable drugs under the OPPS were
paid at ASP + 5 percent in 2008 and ASP + 4 percent in 2009.
The disparate payment rates and policies are evident for anti-cancer
drugs. Such drugs may be provided in a physician office, hospital
outpatient department, or, for certain drugs, through an infusion
pump in a beneficiary’s home. Table 3 shows the first quarter 2009
payment rate in these different settings for four cancer drugs. OPPS
payment rates for drugs are consistently lower than physician office
rates. DME rates may be considerably above or slightly below payment rates in other settings. Payment for some DME drugs is more
than nine times the amount paid in other settings. Whereas the ASPs
are updated quarterly, the payment rates for DME-provided drugs
are frozen at the October 1, 2003, AWP.27

Table 3

Payment May Vary Depending
on Site of Service
HCPCS
Code

Physician
Office

J9040

$ 31.83

Doxil

J9001

$ 441.25

$ 432.93

$ 393.48

Cladribine

Leustatin

J9065

$ 29.25

$ 28.70

$ 61.72

Trastuzumab

Herceptin

J9355

$ 61.64

$ 60.48

$ 58.13

Generic Name

Trade
Name

2 0 0 9 Pay m e n t R at e s

Bleomycin sulfate Blenoxane
Doxorubicin HCl liposome

Hospital Outpatient
Department

Packaged

(not paid separately)

DME External
Infusion Pump
$ 289.37

Source: CMS, "January 2009 ASP Pricing File," available at www.cms.hhs.gov/McrPartBDrugAvgSalesPrice/01a1_2009aspfiles.
asp#TopOfPage; and "January 2009 OPPS Addendum B," available at www.cms.hhs.gov/HospitalOutpatientPPS/AU/list.asp?filterType=
none&filterByDID=0&sortByDID=3&sortOrder=descending&intNumPerPage=10.
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B e n e f i cia r y O u t- of- Po cke t C o s t s

In most cases, beneficiaries in traditional Medicare pay a portion of
the cost of their health services. For Part B drugs, once a beneficiary
meets the annual deductible, the Medicare program pays 80 percent
of the total payment amount and the beneficiary is responsible for the
remaining 20 percent (called the coinsurance or cost-sharing). Therefore, the higher the total payment amount, the higher the beneficiary
coinsurance amount. Depending on the beneficiary’s situation, the
coinsurance may be paid by the Medicaid program, a supplemental
insurance plan, or by the beneficiary themselves. Almost 90 percent
of beneficiaries have some form of supplemental coverage to help
meet their cost-sharing requirements.28 Under Part B, the beneficiary
continues to be responsible for 20 percent of the cost of their drugs
no matter how much they have already spent on drugs; there is no
protection against catastrophic costs as exists under Part D.
Decisions about the specific drug that is provided and the setting
in which that drug is administered can have significant effect on
the amount the beneficiary will pay out of pocket for the drug. The
disparate payment rates shown in Table 3 result in equally disparate beneficiary cost-sharing. For example, a beneficiary receiving
cladribine for treatment of hairy cell leukemia would be responsible
for $5.85 for every unit administered in a physician office, $5.74 for
every unit administered in a hospital outpatient department, and
$12.34 for every unit administered through a DME infusion pump.
Understanding the effect of drug administration choices on beneficiary cost-sharing is further complicated when Part D is taken into
consideration. In some instances, physicians and beneficiaries may
have a choice between multiple treatment options, some of which are
covered under Part B and others under Part D. Appendix B describes
key elements of Part D cost-sharing. As a percentage, coinsurance
under Part B tends to be lower than under Part D (20 percent compared with 25 percent). However, each Part D plan negotiates its own
prices for covered drugs, and that price may be lower than the price
for the Part B alternative.29 Therefore, even though the coinsurance
percentage tends to be higher under Part D, the amount the beneficiary has to pay out of pocket may be lower for a treatment option
under Part D if the beneficiary is enrolled in a plan with a negotiated
price below the payment rate for the Part B option. In addition, Part
D cost-sharing for the same drug can increase or decrease over the
course of the year depending on the beneficiary’s total drug costs
15
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under Part D. See Appendix B for an example illustrating the financial impact of choosing a treatment option under Part B or Part D.

ASSESSING PART B DRUG PAY M EN T P O L ICY
The Medicare Modernization Act of 2003 (MMA) changed the basis
of payment for Part B drugs to better align Medicare payment with
the actual prices paid. Prior to 2005, Medicare payment generally exceeded costs, in some instances by more than 600 percent.30 Prior to
the passage of the MMA, spending on drugs administered in physician offices was increasing at 25 percent per year. With the implementation of MMA payment changes in 2005, actual spending dropped
almost 8 percentage points. Since then, Medicare spending on Part B
drugs has started to increase again, although at a less rapid pace.31
With the transition to ASP, physicians and suppliers raised concerns
that Medicare beneficiaries would no longer have access to all drugs,
or that beneficiaries in certain parts of the country, such as rural
areas, would have to travel farther to receive Part B drugs. Congress
mandated that Medicare pay 6 percent more than ASP with the expectation that most physicians and suppliers would be able to purchase drugs below that rate. Studies of the transition suggest that
this expectation is being met. MedPAC assessed the impact of payment changes for oncology services and found that neither access
nor quality of care was affected. Both small and large practices were
able to purchase drugs for less than the Medicare payment rate.32
GAO similarly found that oncology practices were generally able to
purchase the most-used chemotherapy drugs at or below ASP.33
Some observers note that the transition to ASP revises the calculation
of the payment amount but does not fundamentally change the way
Medicare pays for Part B drugs, nor does it remove the incentives
to “game” the system. The Medicare payment rate still exceeds the
sales price of most drugs. Further, because the difference between
cost and the payment rate is smaller under the ASP methodology
than under AWP, the incentive to maximize profits by providing
greater quantities of drugs may have increased.34
If Medicare payment rates are not so low as to negatively affect beneficiary access to those drugs, are they too high? Some observers point
to rates paid by other government agencies such as the Department
of Veterans Affairs, Department of Defense, or the Indian Health
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Service, which are typically below the Medicare amount, and conclude that Medicare is paying too much. They recommend setting
the Medicare payment at the price paid by these other programs.
Critics call such an approach shortsighted because of the size of the
Medicare program and the number of sales that would then occur
at the lower rates if those prices were adopted. They predict that
any Medicare savings would be temporary because manufacturers
would increase their price to all entities to avoid the mandated prices
to the enormous Medicare population. Expenditures under the other
programs, they argue, would also increase.35

CONC LUSION
Changes under the MMA appear to have addressed concerns about
significant overpayments by Medicare for Part B drugs. However
Part B drugs continue to account for a sizeable portion of total Part
B spending. The extent to which Part B drugs are included in reforms, such as bundled payments, intended to better align payment
incentives to avoid overutilization of services is a tough policy decision. Such decisions must be made recognizing both the complicated
framework of Part B coverage and payment and its complex interaction with Part D coverage.
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Appendix A
Acronym

Drug Pricing Alphabet Soup
Program
Used By...

Treatment of
Discounts and Rebates

Term

Description

AWP

Average
Wholesale
Price

Price listed in certain compendia
(such as Red Book, Price Alert, or
First Databank)

Medicare
Medicaid

Does not include any
rebates or discounts

AMP

Average
Manufacturer’s
Price

Average price paid to the manufacturer for the drug in the United States
by wholesalers for drugs distributed
to the retail pharmacy class of trade

Medicaid

Includes discounts other
than customary prompt
pay discounts.

ASP

Average
Sales Price

Average price for sales to all purchasers excluding sales that are exempt from the Medicaid best price
calculation

Medicare

Includes volume discounts,
prompt pay discounts, cash
discounts, free goods that
are contingent on any purchase requirement, chargebacks, and rebates

——

Best Price

Lowest price available to any wholesaler, retailer, provider, HMO, nonprofit entity or government entity
excluding sales to: IHS, VA, DOD,
or certain Public Health Service
programs; Federal Supply Schedule; state pharmaceutical assistance
programs; Part D plans or qualified
retiree drug subsidy plans

Medicaid

Includes cash discounts, free
goods that are contingent
on any purchase requirement, volume discounts,
and rebates

Wholesale
Acquisition
Cost

The manufacturer’s list price for
a drug to wholesalers or direct
purchasers

Medicare
Medicaid

Does not include any rebates or discounts

Widely
Available
Market Price

Price that a prudent physician or
supplier would pay for the drug
or biological as determined by the
HHS Inspector General

Medicare

Includes discounts, rebates,
and other price concessions
routinely made available
to prudent physicians or
suppliers

WAC

WAMP
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Appendix B
Weighing the Options
Is Part B or Part D
Better for the Beneficiary?

For some conditions, like rheumatoid arthritis or some forms of cancer,
available drug treatments include options that are covered under Part
B and others that are covered under Part D. Even if only financial (not
clinical) considerations are taken into account, determining whether a
Part B drug or a Part D drug is right for a beneficiary is complicated.

Consider the following scenario...

Part D

Beneficiary A and Beneficiary B are enrolled in Part
D plans. Both have annual Part D drug costs and out-ofpocket cost-sharing (deductible and coinsurance).

Beneficiary A

Beneficiary B

Drug costs

$ 1,200

$ 6,000

Cost-sharing

$ 595

$ 4,196

Suppose both beneficiaries are diagnosed with a new condition for which there are two treatment
options. The first option is a Part B drug (Drug X) that costs $1,000 a month. The second option is a Part D
drug (Drug Y) that costs $500 a month.
This table shows the impact on
the out-of-pocket costs for each
beneficiary of choosing either
Drug X or Drug Y.

Beneficiary A

Out-of-Pocket Costs

Drug costs

Beneficiary B

Drug X

Drug Y

Drug X

Drug Y

$ 12,000

$0

$ 12,000

$0

Part B

$ 2,400
$0
$ 2,400
$0
Cost-sharing
As this example shows, the bot$ 1,200
$ 7,200
$ 6,000
$ 12,000
Drug costs
tom line can be surprising. For
Part D
Beneficiary A, who has relatively
$ 595
$ 4,402
$ 4,196
$ 4,642
Cost-sharing
low drug costs, choosing Drug
$ 4,402
$ 6,596
$ 4,642
Total Drug Cost-sharing $ 2,995
X that costs twice as much as
Drug Y actually results in lower
out-of-pocket costs. This happens because, typically under Part D, the coinsurance percentage changes as
the beneficiary’s drug costs increase. The percentage starts at 25 percent for the initial cost-sharing period,
increases to 100 percent after that, and then drops to 5 percent when the beneficiary qualifies for catastrophic
coverage. In contrast, Part B coinsurance is constant at 20 percent.

Using Drug Y would increase Beneficiary A’s Part D drug costs significantly, but not enough to qualify for
catastrophic coverage. Beneficiary B already had relatively high Part D drug costs. For him, choosing Drug
Y would result in lower out-of-pocket costs because the additional Part D drug costs would qualify him for
catastrophic coverage. There is no catastrophic coverage for Part B drugs.
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